AR063977A1 - Enantiomero [r] puro de 5-{[2-fluoro-4-(2-oxo-2h-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido [r]-5-metil-4, 5-dihidro-pirazol-1, 5-dicarboxilico, un metodo para la preparacion del mencionado compuesto, una composicion farmaceutica que lo comprende, formas cristalinas del mismo y - Google Patents

Enantiomero [r] puro de 5-{[2-fluoro-4-(2-oxo-2h-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido [r]-5-metil-4, 5-dihidro-pirazol-1, 5-dicarboxilico, un metodo para la preparacion del mencionado compuesto, una composicion farmaceutica que lo comprende, formas cristalinas del mismo y

Info

Publication number
AR063977A1
AR063977A1 ARP070105244A ARP070105244A AR063977A1 AR 063977 A1 AR063977 A1 AR 063977A1 AR P070105244 A ARP070105244 A AR P070105244A AR P070105244 A ARP070105244 A AR P070105244A AR 063977 A1 AR063977 A1 AR 063977A1
Authority
AR
Argentina
Prior art keywords
compound
amide
phenyl
formula
acid
Prior art date
Application number
ARP070105244A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063977(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR063977A1 publication Critical patent/AR063977A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas de 5-{[2-Fluoro-4-(2-oxo-2H-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido (R)-5-metil-4,5-dihidro-pirazol-1,5-dicarboxílico, procedimientos y uso del compuesto o de las composiciones farmacéuticas del mismo para tratar enfermedades caracterizadas por trombosis anomala en mamíferos. Forma cristalina de 5-{[2-fluoro-4-(2-oxo-2H-piridin-1-iI)-fenil]-amida} 1-[(4-cloro-fenil)-amida} del ácido (R)-5-metil-4,5-dihidro- pirazol-1,5-dicarboxílico, se provee además un método para la preparacion del mismo. Reivindicacion 1: El compuesto 5-{[2-Fluoro-4-(2-oxo-2H-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido (R)-5-metil-4,5-dihidro-pirazol-1,5-dicarboxílico, en el que el enantiomero (R) es sustancialmente puro. Reivindicacion 20: Un procedimiento para preparar 5-{[2-fluoro-4-(2-oxo-2H-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido (R)-5-metil-4,5-dihidro-pirazol-1,5-dicarboxílico que comprende: Etapa (a) (1) hacer reaccionar el compuesto de formula (11) con cloruro de metacriloílo en presencia de un disolvente y una base; o (2) hacer reaccionar un compuesto de formula (11)con cloruro de litio, trietilamina y anhídrido 2-metilacrílico; para dar un compuesto de formula (12); Etapa (b) hacer reaccionar el compuesto de formula (12) con trimetilsilil diazometano, tratamiento con un ácido diluido y aislamiento para producir un compuesto de formula (13); Etapa (c) tratamiento del compuesto de formula (13) con un isocianato y una base suave en un disolvente para dar un compuesto de formula (14); Etapa (d) retirada del auxiliar quiral para dar un compuesto de formula (15) y Etapa (e) acoplamiento del compuesto de formula (15) con un compuesto de formula (3) para producir el compuesto deseado.
ARP070105244A 2006-11-29 2007-11-27 Enantiomero [r] puro de 5-{[2-fluoro-4-(2-oxo-2h-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido [r]-5-metil-4, 5-dihidro-pirazol-1, 5-dicarboxilico, un metodo para la preparacion del mencionado compuesto, una composicion farmaceutica que lo comprende, formas cristalinas del mismo y AR063977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86771406P 2006-11-29 2006-11-29

Publications (1)

Publication Number Publication Date
AR063977A1 true AR063977A1 (es) 2009-03-04

Family

ID=39032289

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105244A AR063977A1 (es) 2006-11-29 2007-11-27 Enantiomero [r] puro de 5-{[2-fluoro-4-(2-oxo-2h-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido [r]-5-metil-4, 5-dihidro-pirazol-1, 5-dicarboxilico, un metodo para la preparacion del mencionado compuesto, una composicion farmaceutica que lo comprende, formas cristalinas del mismo y

Country Status (11)

Country Link
US (1) US20080171773A1 (es)
EP (1) EP2086962A1 (es)
JP (1) JP2010511034A (es)
AR (1) AR063977A1 (es)
CA (1) CA2670595A1 (es)
CL (1) CL2007003349A1 (es)
GT (1) GT200700105A (es)
PE (1) PE20081498A1 (es)
TW (1) TW200831090A (es)
UY (1) UY30745A1 (es)
WO (1) WO2008065503A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138178A1 (en) * 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
JP5605029B2 (ja) * 2010-07-06 2014-10-15 住友化学株式会社 化合物、樹脂及びレジスト組成物
CN104610259B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104860942B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含双酰胺基和硝基苯基结构的FXa抑制剂及其用途
CN104725374B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含双酰胺基和腈基苯结构的FXa抑制剂及其用途
CN104610257B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade

Also Published As

Publication number Publication date
US20080171773A1 (en) 2008-07-17
UY30745A1 (es) 2008-07-03
GT200700105A (es) 2008-11-04
JP2010511034A (ja) 2010-04-08
CA2670595A1 (en) 2008-06-05
WO2008065503A1 (en) 2008-06-05
EP2086962A1 (en) 2009-08-12
CL2007003349A1 (es) 2008-06-06
PE20081498A1 (es) 2008-11-08
TW200831090A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
AR063977A1 (es) Enantiomero [r] puro de 5-{[2-fluoro-4-(2-oxo-2h-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido [r]-5-metil-4, 5-dihidro-pirazol-1, 5-dicarboxilico, un metodo para la preparacion del mencionado compuesto, una composicion farmaceutica que lo comprende, formas cristalinas del mismo y
WO2007104034A3 (en) Glucokinase activators
WO2005087771A3 (de) 5,6-dialkyl-7-amino-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
HRP20050641A2 (en) New carboxylic acids and the esters thereof, pharmaceutical compositions containing these compounds and processes for the preparation thereof
WO2007035629A3 (en) Process for the preparation of pyrimidinedione derivatives
WO2008075376A8 (en) Polymorphic forms of bortezomib and process for their preparation
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
EA200802054A1 (ru) Ингибиторы фермента
WO2006024387A3 (de) Biphenylthiazolcarboxamide
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
CO5690637A2 (es) Tiazol-(bi) cicloalquil-carboxanilidas
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
SE0300957D0 (sv) Chemical compounds
WO2006079720A8 (fr) Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants
WO2005087770A3 (de) 5, 6-dihydrocarbyl-7-amino-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
ATE388154T1 (de) Kristalline form von cefdinir-ammoniumsalz als zwischenprodukt für die herstellung von reinem cefdinir
TW200800942A (en) Chemical compounds
ATE466010T1 (de) Verfahren zur herstellung von candesartan
DE602006002650D1 (de) Verfahren zur Herstellung von Paroxetin Hydrochlorid Hemihydrat
TW200722419A (en) Chemical compounds
MX2010007923A (es) Forma cristalina de abacavir que esta esencialmente libre de disolvente.
MX2009005104A (es) Mezclas fungicidas.
DE602004031237D1 (de) Verfahren zur herstellung von hochreinem (meth)acryloyloxyalkylisocyanat

Legal Events

Date Code Title Description
FA Abandonment or withdrawal